Development and in vitro/in vivo Evaluation of a Silastic Intravaginal Ring for Mifepristone Delivery.

about

Development and in vitro/in vivo Evaluation of a Silastic Intravaginal Ring for Mifepristone Delivery.

Item

http://www.wikidata.org/entity/Q35851257

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Development and in vitro/in vi ...... ing for Mifepristone Delivery.

@ast

Development and in vitro/in vi ...... ing for Mifepristone Delivery.

@en

type

Item

label

Development and in vitro/in vi ...... ing for Mifepristone Delivery.

@ast

Development and in vitro/in vi ...... ing for Mifepristone Delivery.

@en

prefLabel

Development and in vitro/in vi ...... ing for Mifepristone Delivery.

@ast

Development and in vitro/in vi ...... ing for Mifepristone Delivery.

@en

P1476

Development and in vitro/in vi ...... ing for Mifepristone Delivery.

@en

P2093

M Ning

http://www.w3.org/2001/XMLSchema#string

X Duan

http://www.w3.org/2001/XMLSchema#string

P2860

Simultaneous determination of mifepristone and monodemethyl-mifepristone in human plasma by liquid chromatography-tandem mass spectrometry method using levonorgestrel as an internal standard: application to a pharmacokinetic study.

Improved quality of life is partly explained by fewer symptoms after treatment of fibroids with mifepristone.

Review of medical abortion using mifepristone in combination with a prostaglandin analogue.

Mifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery.

Preparation and evaluation of intravaginal ring containing drospirenone.

The contraceptive vaginal ring.

Advances in microbicide vaginal rings.

Combining prevention of HIV-1, other sexually transmitted infections and unintended pregnancies: Development of dual-protection technologies.

Vaginal ring contraception.

Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines.

P304

335-342

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4103/0250-474X.159671

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26180280

http://www.w3.org/2001/XMLSchema#string

P932

4502149

http://www.w3.org/2001/XMLSchema#string